TANC2: A Potential Drug Target and Biomarker for KIAA1636 in Cancer

Target Name: TANC2

NCBI ID: G26115

TANC2

TANC2: A Potential Drug Target and Biomarker for KIAA1636 in Cancer

Cancer is a leading cause of morbidity and mortality worldwide, with over 80% of cancer deaths occurring in developed countries. The development of new therapeutic approaches to treat cancer is crucial for improving patient outcomes. One of the promising strategies is the identification of potential drug targets and biomarkers. TANC2, a gene encoding a protein known as TAN, has been identified as a potential drug target and biomarker for cancer. This article will discuss the biology of TANC2, its potential as a drug target, and its potential as a biomarker for cancer.

The biology of TANC2

TANC2 is a 21 kDa protein that is expressed in various tissues, including brain, heart, lungs, and gastrointestinal tract. It is a member of the TAN family, which includes proteins involved in cell signaling pathways, including TAN1 and TAN2. TANC2 is composed of a unique N-terminal domain, a catalytic C-terminal domain, and a unique C-terminal region that contains a leucine-rich repeat (LRR) domain.

The functions of TANC2 are not well understood, but its expression is regulated by various signaling pathways, including TGF-β, NF-kappa-B, and AP-1. TANC2 has been shown to play a role in cell signaling pathways, including the regulation of cell adhesion, migration, and invasion. TANC2 has also been shown to be involved in the regulation of cell apoptosis, a critical event in cancer progression.

Potential drug target

TANC2 has been identified as a potential drug target due to its unique structure and its involvement in various signaling pathways. One of the potential drug targets for TANC2 is the inhibition of its catalytic activity, which could result in the inhibition of cell signaling pathways. This could result in the inhibition of cell growth, migration, and invasion, which could be a potential therapeutic approach for cancer treatment.

TANC2 has been shown to interact with various signaling molecules, including TGF-β, NF-kappa-B, and AP-1. Therefore, inhibitors of TANC2 could potentially be developed by targeting these molecules. One of the potential strategies for inhibiting TANC2 is the use of small molecules, such as inhibitors of the enzymes that regulate TANC2. These inhibitors could be administered to cancer cells to inhibit TANC2 catalytic activity and potentially inhibit cell signaling pathways.

Biomarker potential

TANC2 has also been identified as a potential biomarker for cancer due to its expression and its involvement in various signaling pathways. The expression of TANC2 has been shown to be regulated by various signaling pathways, including TGF-β, NF-kappa-B, and AP-1. Therefore, the expression of TANC2 could be used as a biomarker for cancer, particularly in tumors that are resistant to traditional therapies.

The detection of TANC2 expression and its levels could be used as a biomarker for cancer diagnosis and monitoring. This could be done using techniques such as qRT-PCR, western blotting, and immunofluorescence. The levels of TANC2 expression could also be used as a biomarker for cancer grading and recurrence.

Conclusion

TANC2 is a unique protein that has been identified as a potential drug target and biomarker for cancer. Its functions and interactions with various signaling molecules make it a promising target for the development of new therapeutic approaches for cancer treatment. Further research is needed to understand the full potential of TANC2 as a drug target and biomarker for cancer.

Protein Name: Tetratricopeptide Repeat, Ankyrin Repeat And Coiled-coil Containing 2

Functions: Scaffolding protein in the dendritic spines which acts as immobile postsynaptic posts able to recruit KIF1A-driven dense core vesicles to dendritic spines

The "TANC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TANC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets